Who's who

3 Houston innovators to know this week

Yael Katz, Topper Luciani, and Dorit Donoviel are this week's Houston innovators to know. Courtesy photos

Houston is full of innovative people looking to make an impact — whether it's in the health tech, fashion, or science industries.

This week's innovators to know represent different industries within Houston, but they are all looking to leave a legacy in making a difference.

Yael Katz, co-founder and CEO of BrainCheck

Photo courtesy of BrainCheck

Yael Katz has seen the company she co-founded grow tenfold in its almost five years, and now she's watching that growth from a corner office with a great view of Houston.

BrainCheck, a cognitive assessment startup that has developed a software tool for primary care doctors to use to assess their patients' cognitive health, has moved into a new office space in the West University area following a series A round of fundraising.

"It's pretty exciting to have reached this milestone where we need more space," Yael Katz, co-founder and CEO of BrainCheck, tells InnovationMap. "We were pretty much bursting at the seams in our old office." Read more.

Topper Luciani, founder and CEO of Goodfair

Photo courtesy of Goodfair

With the rise of fast fashion — in which huge clothing lines rapidly produce cheap clothing for consumers, humans are cycling through clothing at a detrimental rate.

According to a report from Business Insider, the fashion industry contributes 10 percent of the world's carbon emissions, is the second-largest user of the earth's water supply, and pollutes the oceans with microplastics.

"I realized that there was too much stuff out there," says Topper Luciani, founder and CEO of Houston-based Goodfair, "and there is an environmental crisis being caused by the clothing industry. They're manufacturing so many items, they're using slave labor, they're pumping dyes and other chemicals into rivers. It's absolutely wild." Read more.

Dorit Donoviel, director of the Translational Research Institute for Space Health

Libby Neder Photography

On the most recent episode of the Houston Innovators Podcast, Dorit Donoviel speaks of space health needs in ways that sound like futuristic science fiction. However, the director of the Translational Research Institute of Space Health is actively seeking solutions for issues and needs for living in space.

TRISH works hand in hand with NASA's Human Research Program to identify the program's biggest concerns, and then tap into professors, researchers, and scientists from Baylor College of Medicine, California Institute of Technology, the Massachusetts Institute for Technology, and other partners in order to innovate solutions.

"Everyone tosses the word 'innovation' around, but that means, to us, taking risks in science. Health care, in particular, is very risk averse, but the space industry is taking risks every single day when they put people in a rocket and hurl them into space," Donoviel says on the podcast. "If we're going to mars, for example, we are going to put people at risk." Read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News